MX381590B - Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. - Google Patents

Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.

Info

Publication number
MX381590B
MX381590B MX2019003093A MX2019003093A MX381590B MX 381590 B MX381590 B MX 381590B MX 2019003093 A MX2019003093 A MX 2019003093A MX 2019003093 A MX2019003093 A MX 2019003093A MX 381590 B MX381590 B MX 381590B
Authority
MX
Mexico
Prior art keywords
crystalline forms
pharmaceutical compositions
phosphonopropionyl
pyrrolidine
piperazine
Prior art date
Application number
MX2019003093A
Other languages
English (en)
Spanish (es)
Other versions
MX2019003093A (es
Inventor
Daniel Leuenberger
Raumer Markus Von
Stefan Reber
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2019003093A publication Critical patent/MX2019003093A/es
Publication of MX381590B publication Critical patent/MX381590B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2019003093A 2016-09-22 2017-09-21 Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico. MX381590B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (2)

Publication Number Publication Date
MX2019003093A MX2019003093A (es) 2019-07-18
MX381590B true MX381590B (es) 2025-03-12

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003093A MX381590B (es) 2016-09-22 2017-09-21 Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.

Country Status (27)

Country Link
US (4) US10730896B2 (cg-RX-API-DMAC7.html)
EP (2) EP3981774A1 (cg-RX-API-DMAC7.html)
JP (1) JP7097369B2 (cg-RX-API-DMAC7.html)
KR (1) KR102552795B1 (cg-RX-API-DMAC7.html)
CN (1) CN109715639B (cg-RX-API-DMAC7.html)
AU (1) AU2017331930B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037794A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000728A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125052T1 (cg-RX-API-DMAC7.html)
DK (1) DK3515924T3 (cg-RX-API-DMAC7.html)
EA (1) EA201990723A1 (cg-RX-API-DMAC7.html)
ES (1) ES2908572T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220234T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057772T2 (cg-RX-API-DMAC7.html)
IL (1) IL265445B2 (cg-RX-API-DMAC7.html)
LT (1) LT3515924T (cg-RX-API-DMAC7.html)
MA (1) MA46266B1 (cg-RX-API-DMAC7.html)
MX (1) MX381590B (cg-RX-API-DMAC7.html)
MY (1) MY193080A (cg-RX-API-DMAC7.html)
PH (1) PH12019500567B1 (cg-RX-API-DMAC7.html)
PL (1) PL3515924T3 (cg-RX-API-DMAC7.html)
PT (1) PT3515924T (cg-RX-API-DMAC7.html)
RS (1) RS62946B1 (cg-RX-API-DMAC7.html)
SI (1) SI3515924T1 (cg-RX-API-DMAC7.html)
TW (1) TWI752086B (cg-RX-API-DMAC7.html)
UA (1) UA124073C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018055016A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
US20240317784A1 (en) 2021-07-13 2024-09-26 Viatris Asia Pacific Pte. Ltd. Process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
PL1611144T3 (pl) 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
BRPI0617636A2 (pt) 2005-10-21 2012-04-17 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
BRPI0810462A2 (pt) 2007-04-23 2014-10-14 Sanofi Aventis Derivados de quinolina-carboxamida como antagonistas de p2y12
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
CN102369197B (zh) 2009-04-08 2013-11-06 埃科特莱茵药品有限公司 作为adp受体拮抗剂的6-(3-氮杂-二环[3.1.0]己-3-基)-2-苯基-嘧啶
AU2010240527A1 (en) 2009-04-22 2011-12-01 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as P2Y12 receptor antagonists
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
TW201813965A (zh) 2018-04-16
WO2018055016A1 (en) 2018-03-29
MY193080A (en) 2022-09-26
HRP20220234T1 (hr) 2022-05-13
EP3515924B1 (en) 2021-12-15
IL265445B2 (en) 2024-05-01
US20200017534A1 (en) 2020-01-16
US20220275011A1 (en) 2022-09-01
CA3037794A1 (en) 2018-03-29
SI3515924T1 (sl) 2022-04-29
US20250163086A1 (en) 2025-05-22
PH12019500567B1 (en) 2024-01-31
HUE057772T2 (hu) 2022-06-28
IL265445A (en) 2019-05-30
PT3515924T (pt) 2022-03-11
JP2019529553A (ja) 2019-10-17
LT3515924T (lt) 2022-03-10
KR20190052704A (ko) 2019-05-16
MX2019003093A (es) 2019-07-18
AU2017331930B2 (en) 2021-07-15
PH12019500567A1 (en) 2019-11-18
RS62946B1 (sr) 2022-03-31
TWI752086B (zh) 2022-01-11
PL3515924T3 (pl) 2022-04-11
NZ750772A (en) 2023-10-27
US11365209B2 (en) 2022-06-21
US20210009614A1 (en) 2021-01-14
CY1125052T1 (el) 2024-02-16
EA201990723A1 (ru) 2019-10-31
US10730896B2 (en) 2020-08-04
ES2908572T3 (es) 2022-05-03
AU2017331930A1 (en) 2019-03-07
UA124073C2 (uk) 2021-07-14
KR102552795B1 (ko) 2023-07-06
EP3981774A1 (en) 2022-04-13
MA46266B1 (fr) 2022-02-28
BR112019004845A2 (pt) 2019-06-04
CN109715639A (zh) 2019-05-03
IL265445B1 (en) 2024-01-01
JP7097369B2 (ja) 2022-07-07
CN109715639B (zh) 2022-04-19
DK3515924T3 (da) 2022-03-21
MA46266A (fr) 2019-07-31
EP3515924A1 (en) 2019-07-31
US12227532B2 (en) 2025-02-18
CL2019000728A1 (es) 2019-07-05

Similar Documents

Publication Publication Date Title
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CL2017002650A1 (es) Compuestos novedosos
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2016001895A1 (es) Compuestos
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX381590B (es) Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
BR112017009852A2 (pt) composto, composição, e, usos de um composto